Your session is about to expire
← Back to Search
Magrolimab for Neuroblastoma
Study Summary
This trial is to find out the benefits and side effects of magrolimab and dinutuximab for treating patients with relapsed neuroblastoma or relapsed osteosarcoma. Magrolimab and dinutuximab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. The combination of magrolimab and dinutuximab may shrink or stabilize relapsed or refractory neuroblastoma or relapsed osteosarcoma.
- Neuroblastoma
- Osteosarcoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 1 & 2 trial • 78 Patients • NCT02953782Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Do I meet the criteria necessary to participate in this medical experiment?
"In order to be eligible for the trial, prospective participants must have a diagnosis of osteosarcoma and fall within the age range of 1 year old up to 35 years. Currently, 82 candidates are needed to join this research initiative."
What prior research has examined the efficacy of Magrolimab?
"Presently, 33 clinical trials involving Magrolimab are ongoing worldwide. Of those studies, 7 have progressed to Phase 3. These medical experiments primarily take place in San Francisco but 1538 sites across the globe also carry out research for this drug's efficacy."
Is there room for additional participants in this research experiment?
"Affirmative. According to the information that is accessible on clinicaltrials.gov, this experiment has been actively recruiting volunteers since April 16th 2021 and was most recently amended on November 8th 2022. The research team hopes to find 82 participants from 11 different medical sites."
How many Canadian medical centers are currently studying this experimental protocol?
"At the time of writing, Children's Hospital Colorado in Aurora, Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center in Houston and British Columbia Children's Hospital in Vancouver are actively enrolling patients for this trial. Moreover, there are 11 other medical centres that may also offer participation."
Is geriatric participation being sought in this scientific analysis?
"This research is seeking participants aged between 1 and 35 years old."
Has Magrolimab been certified by the Food and Drug Administration?
"As this is a Phase 1 clinical trial, the safety of Magrolimab has been evaluated as low on our scale from one to three. This reflects limited evidence supporting both its efficacy and security."
What is the total number of participants accepted for this trial?
"This clinical trial necessitates 82 eligible patients to join in and has multiple sites, such as Children's Hospital Colorado at Aurora, Colorado or Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center located in Houston, Texas."
Share this study with friends
Copy Link
Messenger